Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective

Health Policy

Volumn 81, Issue 2-3, 2007, Pages 358-367

  Bergström, Gina ^a   Karlberg, Ingvar ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Decentralized responsibility; Financial incentives; Pharmaceutical budgets; Sweden

Indexed keywords

ARTICLE; BUDGET; COST CONTROL; DRUG COST; DRUG USE; HEALTH CARE MANAGEMENT; HEALTH ECONOMICS; HUMAN; INTERVIEW; MODEL; OUTPATIENT; PRESCRIPTION; RESOURCE ALLOCATION; RESPONSIBILITY; SWEDEN;

COST CONTROL; HUMANS; INTERVIEWS; MODELS, ORGANIZATIONAL; OUTPATIENTS; PHARMACEUTICAL PREPARATIONS; POLITICS; SOCIAL RESPONSIBILITY; STATE MEDICINE; SWEDEN;

EID: 33947268532     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.07.006     Document Type: Article

References (26)

1. Lundkvist J. Pricing and reimbursement of drugs in Sweden. European Journal of Health Economics 3 1 (2002) 66-70
2. Henriksson F., Hjortsberg C., and Rehnberg C. Pharmaceutical expenditure in Sweden. Health Policy 47 2 (1999) 125-144
3. Utredningen om läkemedelsförmånen, Den nya läkemedelsförmånen: slutbetänkande. Stockholm: Fritzes offentliga publikationer; 2000.
4. Gerdtham U.G., and Lundin D. Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics 22 1 (2004) 29-42
5. Ljungkvist M.O., Andersson D., and Gunnarsson B. Cost and utilisation of pharmaceuticals in Sweden. Health Policy 41 Suppl. (1997) S55-S69
6. McGavock H. Strategies to improve the cost effectiveness of general practitioner prescribing. An international perspective. Pharmacoeconomics 12 3 (1997) 307-311
7. Drummond M., and Jonsson B. Moving beyond the drug budget silo mentality in Europe. Value Health 6 Suppl. 1 (2003) S74-S77
8. Saltman R., and Figueras J. European health care reform: analysis of current strategies. WHO Regional Publications. European Series vol. 72 (1997), World Health Organization Regional Office for Europe, Copenhagen
9. Kane N.M., and Saltman R.B. Comparative experience in home care and pharmaceutical policy. Health Policy 41 Suppl. (1997) S1-S7
10. Act (2002:160) on Pharmaceutical Benefits, etc. In: SFS; 2002.
11. Mintzberg H. Structure in fives: designing effective organizations. International ed. (1993), Prentice-Hall International, Englewood Cliffs, NJ
12. Mosca I. Is decentralisation the real solution? A three country study. Health Policy 77 1 (2006) 113-120
13. Yin R.K. Case study research: design and methods. Applied social research methods series. 2nd ed. vol. 5 (1994), Sage, Thousand Oaks, CA
14. Schoffski O., and Graf von der Schulenburg J.M. Unintended effects of a cost-containment policy: results of a natural experiment in Germany. Social Science and Medicine 45 10 (1997) 1537-1539
15. von der Schulenburg J.M. Management of cost and utilization of pharmaceuticals in Germany. Health Policy 41 Suppl. (1997) S45-S53
16. Schneeweiss S., Schoffski O., and Selke G.W. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. Health Policy 44 3 (1998) 253-260
17. Delnoij D., and Brenner G. Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding?. Health Policy 52 3 (2000) 157-169
18. Ess S.M., Schneeweiss S., and Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21 2 (2003) 89-103
19. Harris C.M., and Scrivener G. Fundholders' prescribing costs: the first five years. BMJ 313 7071 (1996) 1531-1534
20. Wilton P., and Smith R.D. Devolved budgetary responsibility in primary care. A cross-country assessment of the impact on efficiency. European Journal of Health Economics 3 1 (2002) 17-25
21. Mossialos E., Mrazek M., and Walley T. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. European observatory on health systems and policies (2004), Open University Press, Maidenhead
22. Fattore G., and Jommi C. The new pharmaceutical policy in Italy. Health Policy 46 1 (1998) 21-41
23. Baines D.L., and Parry D.J. Analysis of the ability of the new needs adjustment formula to improve the setting of weighted capitation prescribing budgets in English general practice. BMJ 320 7230 (2000) 288-290
24. Garrison L., and Towse A. The drug budget silo mentality in Europe: an overview. Value Health 6 Suppl. 1 (2003) S1-S9
25. Whynes D.K., Heron T., and Avery A.J. Prescribing cost savings by GP fundholders: long-term or short-term?. Health Economics 6 2 (1997) 209-211
26. Chaix-Couturier C., Durand-Zaleski I., Jolly D., and Durieux P. Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues. International Journal of Quality Health Care 12 2 (2000) 133-142